Ajanta Pharma (AJP IN): Stellar Q4 Performance; INR3B Buyback Plan Announced
Ajanta Pharma reports strong Q4FY24 results with double-digit revenue and PAT growth, announces INR3.5B buyback plan, and is confident of...
218 Views
Ajanta Pharma (AJP IN): Starts FY24 With Healthy Branded Generics Growth and Improving Margins
Ajanta Pharma has a positive business outlook due to accelerated revenue growth driven by India branded generics business, niche and complex...
370 Views
Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business
Shareholders’ nod for the proposed demerger will create pharmaceutical-focused listed entity, which should pave the way for value unlocking due to...
339 Views
Aurobindo Pharma (ARBP IN): Pain Continues in the U.S. Formulation Business
Aurobindo’s U.S. formulation business is witnessing price erosion, which is impacting the revenue and margin. However, value unlocking in...
303 Views
Para IV Winners and Losers - September 2018
This month’s Para IV developments suggest that there is likely to be benefit to Teva Pharmaceutical Sp Adr (TEVA US) on Vesicare, Soolantra and...
441 Views